Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male

Richard A. Maiella; Kelly M. Staples; Ashokvardhan Veldanda; Richard A. Maiella; Kelly M. Staples; Ashokvardhan Veldanda

doi:10.3934/Allergy.2022003

AIMS Allergy and Immunology

2022, Volume 6, Issue 1: 14-18. doi: 10.3934/Allergy.2022003

Previous Article Next Article

Case report

Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male

1.
Rowan University School of Osteopathic Medicine, 42 E Laurel Rd, Stratford, NJ 08084, USA
2.
Stafford Medical, P.A., 1364 Route 72 West, Manahawkin NJ, 08050, USA

Received: 10 January 2022 Revised: 03 February 2022 Accepted: 15 February 2022 Published: 17 February 2022

With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster.
- vaccine,
- hives,
- COVID-19,
- rash,
- allergy,
- urticaria,
- booster
Citation: Richard A. Maiella, Kelly M. Staples, Ashokvardhan Veldanda. Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male[J]. AIMS Allergy and Immunology, 2022, 6(1): 14-18. doi: 10.3934/Allergy.2022003

Related Papers:

Abstract

With the recent approval of booster vaccinations in the United States for adults who already received their primary vaccinations, millions of adults have been administered the Pfizer-BioNTech or Moderna booster vaccines. Adverse events related to these vaccines continue to be reported and are majority self-limited. In this case report, we present a young male who acquired chronic, migratory dermatographic urticaria two weeks after administration of the Moderna mRNA-1273 COVID-19 vaccine booster.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

RM: conception, design, interpretation of case presentations, writing of manuscript, revision of study material, final approval of manuscript; KS: writing of manuscript, revision of study material, final approval of manuscript; AV: served as scientific advisor and provided care for study patient, attending physician.

References

[1]	(2021) U.S. Food and Drug Administration, Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters.FDA. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters
[2]	Mathieu E, Ritchie H, Ortiz-Ospina E, et al. (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 5: 947-953. https://doi.org/10.1038/s41562-021-01122-8
[3]	Baden LR, El Sahly HM, Essink B, et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med 384: 403-416. https://doi.org/10.1056/NEJMoa2035389
[4]	McMahon DE, Amerson E, Rosenbach M, et al. (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 85: 46-55. https://doi.org/10.1016/j.jaad.2021.03.092
[5]	Gronbeck C, Grant-Kels JM (2021) Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them!. Clin Dermatol 39: 674-687. https://doi.org/10.1016/j.clindermatol.2021.05.027
[6]	Thomas J, Thomas G, Chatim A, et al. (2021) Chronic spontaneous urticaria after COVID-19 vaccine. Cureus 13: e18102. https://doi.org/10.7759/cureus.18102
[7]	Johnston MS, Galan A, Watsky KL, et al. (2021) Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: a case series. JAMA Dermatol 157: 716-720. https://doi.org/10.1001/jamadermatol.2021.1214

Reader Comments

Your name:*

Email:*
© 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)